Uromigos Live 2023-Prostate Cancer

The UromigosUromigos Live 2023 | November 20, 2023
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
View More
The UromigosUromigos Live 2023 | November 20, 2023
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
Tanya Dorff, MDUromigos Live 2023 | November 14, 2023
Drs. Dorff and Agarwal share how crucial it is for mPC patients around the world to undergo germline or somatic testing.
Tanya Dorff, MDUromigos Live 2023 | November 14, 2023
Drs. Hope and Agarwal provide an overview of the SOC for 1L mCRPC prior to TALAPRO-2 and how the SOC has since changed.
Tanya Dorff, MDUromigos Live 2023 | November 14, 2023
Drs. Dorff and Agarwal summarize the toxicities associated with talazoparib for patients with metastatic CRPC.
Tanya Dorff, MDUromigos Live 2023 | November 14, 2023
Drs. Dorff and Agarwal discuss the goals of the TALAPRO-2 study and further understandings that subset analyses provided.
Brian Rini, MD, FASCOUromigos Live 2023 | November 14, 2023
Drs. Rini, Barata, and Hamid discuss takeaways from the session, including trial design and unmet needs in the field.
Michael Morris, MDUromigos Live 2023 | November 8, 2023
Michael Morris, MD, discusses radioligand therapy for prostate cancer, including common practices and new data.
Chandler Park, MDUromigos Live 2023 | November 8, 2023
Dr. Park shares why it is too soon to tell if there is survival benefit to gain from Lu-177 PSMA-617 prior to chemotherapy.
Anis Hamid, MBBSUromigos Live 2023 | November 8, 2023
Dr. Hamid describes how PSMAfore impacts treatment sequencing in mCRPC and how future trials can strengthen control arms.
Alan Tan, MDUromigos Live 2023 | November 8, 2023
Dr. Alan Tan compares the PSMAfore and VISION studies and comments on the controversy regarding OS benefit in the former.
The UromigosThe Uromigos | November 7, 2023
Brian is joined by Drs. Agarwal, Dorff, McKay, and Morris to review the state of radioligand therapy.
Michael Morris, MDUromigos Live 2023 | October 16, 2023
Dr. Morris talks about potential topics to be discussed at the event, such as the PSMAfore trial and data from ESMO.
Rana McKay, MDUromigos Live 2023 | September 25, 2023
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Advertisement
Advertisement